Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5791356 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL9843585 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL25467328 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL3983188 | 0.98 | ALDH1A1 (0.49) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL3983080 | 0.98 | ALDH1A1 (0.49) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL3985705 | 0.96 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL26077288 | 0.96 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL15712143 | 0.91 | PPM1B (0.53) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL360031 | 0.83 | PPM1B (0.47) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL19543310 | 0.82 | PPM1B (0.46) | PPM1BPTPN1PPP1CCALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| WO-1993004070-A1 | SUBSTITUTED ACRYLAMIDO-PENICILLANIC ACID DERIVATIVES | SMITHKLINE BEECHAM, PLC (GB) | 1993-03-04 | — | — | WO | disclosed |
| EP-0421752-A2 | Substituted acrylamido-penicillanic acid derivatives | Beecham Group p.l.c. (GB) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | PPM1B 3491/4885PTPN1 1967/4885PPP1CC 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.